Chronic Insomnia Clinical Trial
Official title:
The Effect of Mindfulness Based Stress Reduction (MBSR) on Patients With Traumatic Brain Injury and Chronic Insomnia
NCT number | NCT03560843 |
Other study ID # | 900001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 12, 2018 |
Est. completion date | September 2019 |
Verified date | June 2018 |
Source | Henry M. Jackson Foundation for the Advancement of Military Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the effects of Mindfulness Based Stress Reduction (MBSR) as an adjunct to usual clinical care for treatment of stress and chronic insomnia for patients with mild to moderate traumatic brain injury (MTBI). MBSR is a standardized protocol of meditation and yoga that has been studied extensively in other populations, however the effects of MBSR have not yet been well studied in the proposed population of service members with a Traumatic Brain Injury (TBI) who are experiencing insomnia.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Patients with mild-to-moderate TBI (as defined by the DoD criteria) 2. Right-handedness 3. Insomnia Severity Index =15 4. DEERS eligible at the time of enrollment 5. Not pregnant 6. Male and female subjects 18 to 60 years old 7. Insomnia disorder per DSM-V criteria Exclusion Criteria: 1. Inability to speak or understand English (because this is a group intervention, it requires a common language) 2. Patients who require assistance with activities of daily living (ADLs) 3. Active practice of meditation and/or yoga or participation in meditation/yoga classes in the last 6 months prior to enrollment 4. Signs or symptoms of upper motor neuron syndrome, any major systemic illness or unstable condition which could interfere with protocol compliance 5. Active psychiatric disease that would interfere with participation in the trial, psychotic features, agitation, or behavioral problems within the last 3 months that could interfere with protocol compliance 6. A history of alcohol/substance abuse or dependence within the past 6 months 7. Any neurosurgical intervention affecting brain parenchyma 8. Unstable seizure activity 9. Concurrent participation in another clinical research trial with investigational drug or previous participation with the last investigational drug administered less than 4 weeks prior to screening 10. Females who are pregnant or planning to become pregnant in 6 months following screening. |
Country | Name | City | State |
---|---|---|---|
United States | Fort Belvoir Community Hospital | Fort Belvoir | Virginia |
Lead Sponsor | Collaborator |
---|---|
Henry M. Jackson Foundation for the Advancement of Military Medicine |
United States,
Azulay J, Smart CM, Mott T, Cicerone KD. A pilot study examining the effect of mindfulness-based stress reduction on symptoms of chronic mild traumatic brain injury/postconcussive syndrome. J Head Trauma Rehabil. 2013 Jul-Aug;28(4):323-31. doi: 10.1097/HTR.0b013e318250ebda. — View Citation
Hubbling A, Reilly-Spong M, Kreitzer MJ, Gross CR. How mindfulness changed my sleep: focus groups with chronic insomnia patients. BMC Complement Altern Med. 2014 Feb 10;14:50. doi: 10.1186/1472-6882-14-50. — View Citation
Johansson B, Bjuhr H, Rönnbäck L. Mindfulness-based stress reduction (MBSR) improves long-term mental fatigue after stroke or traumatic brain injury. Brain Inj. 2012;26(13-14):1621-8. doi: 10.3109/02699052.2012.700082. Epub 2012 Jul 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrease in total score of Insomnia Severity Index (ISI) scale. | compare change in Insomnia Severity Index (ISI, score range 0-28) scores at baseline, 2 week follow up and 6 month follow up. ISI measures severity of insomnia and calculated by adding the scores for all seven items. Results interpretation: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe). A 6 point decrease is considered clinically significant improvement in symptoms of insomnia. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in cognitive function as measured by NIH toolbox | Compare changes in cognitive assessment measured by National Institute of Health (NIH) Toolbox between the groups and at baseline and 2 week follow up within the group. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in PCL-5 (Post Traumatic Stress Disorder Check List-5) score | Compare changes in total scores in PTSD Check List-5 (PCL-5) (range 0-80) scores between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. PCL-5 measures symptoms of PTSD (post traumatic stress disorder) for initial provisional diagnosis, to monitor symptoms before and after treatment and screening individuals for PTSD so they can be appropriately followed by the clinicians. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items. symptom cluster severity scores can be obtained by summing the scores for the items within a given cluster. A provisional PTSD diagnosis can be made by treating each item rated as 2 = "Moderately" or higher as a symptom endorsed, then following the diagnostic rule which requires at least: 1 B item (questions 1-5), 1 C item (questions 6-7), 2 D item | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in RAND-36 (RAND corporation 36 item Health Survey) score | Compare changes in total scores in RAND corporation 36 item Health Survey (RAND-36 range 0-100 on each item) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. RAND-36 measures eight concepts: physical functioning, bodily pain, limitations due to physical health problems, limitations due to emotional or personal problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. It also includes a single item that provides an indication of perceived change in health.Scoring the RAND 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key given in Table 1. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in PHQ-9 (Patient Health Questionnaire 9) score | Compare changes in total scores in Patient Health Questionnaire 9 (PHQ-9, score range 0-27) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. PHQ-9 assesses depression. Scoring: add up all checked boxes on PHQ-9 For every checked Not at all = 0; Several days = 1;More than half the days = 2; Nearly every day = 3, Interpretation of Total (sum of all items) Score: 1-4 Minimal depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderately severe depression; 20-27 Severe depression | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in FSS (Fatigue Severity Scale score) | Compare changes in total scores in Fatigue Severity Scale (FSS, score range 9-63) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on participant. The FSS is a short questionnaire that requires participant to rate their level of fatigue. The FSS questionnaire contains nine statements that rate the severity of participant's fatigue symptoms.A total score of less than 36 suggests that participant may not be suffering from fatigue. A total score of 36 or more suggests that participant may need further evaluation by a physician. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in MAAS (Mindful Attention Awareness Scale score) | Compare changes in total scores in Mindful Attention Awareness Scale (MAAS, score range 15-90) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The trait MAAS is a 15-item scale designed to assess a core characteristic of mindfulness, namely, a receptive state of mind in which attention, informed by a sensitive awareness of what is occurring in the present, simply observes what is taking place. This is in contrast to the conceptually driven mode of processing, in which events and experiences are filtered through cognitive appraisals, evaluations, memories, beliefs, and other forms of cognitive manipulation.To score the scale, simply compute a mean (average) of the 15 items. Higher scores reflect higher levels of dispositional mindfulness. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in PSS (Perceived Stress Scale) | Compare changes in total scores Perceived Stress Scale (PSS, score range 0-40) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The PSS is a global assessment of an individual's perception of psychological stress during the past month. scores are obtained by reversing the scores on the four positive items, e.g., 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4,5, 7, and 8 are the positively stated items.Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Change in NSI (Neurobehavioral Symptom Inventory scale) score | Compare changes in total scores in Neurobehavioral Symptom Inventory (NSI, range 0-88) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The NSI is widely used in the Department of Defense (DoD) for the evaluation of post-concussive symptoms in service members (SMs). In addition, the Department of Veterans Affairs (VA) uses the NSI in its comprehensive traumatic brain injury (TBI) evaluation. Scores are summed at initial visit and follow up visit. number of symptoms of moderate, severe, and very severe intensity and a list of the specific symptoms in each of these rating categories. Change in individual symptom scores of two or more points in a positive direction consistent with recovery (i.e. very severe to moderate, mild or none; severe to mild or none; moderate to none). Change in individual symptom scores of two or more points indicative of symptom worsening or deterioration. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Any changes in blood biomarkers | Compare any changes in biomarkers - cytokines (il-6, IL-10, TNFa), tau, BDNF, IGF-1, amyloid beta 40/42, and melatonin measured at pg/ml at baseline and 2 week follow up. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion | |
Secondary | Changes in SE- sleep efficiency measured by actigraphy devices and polysomnography. | to compare sleep sleep efficiency in % as calculated by total time asleep/total sleep time determined by actigraphy devices and polysomnography. | Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03171519 -
Effects of Exercise and Acupuncture on Chronic Insomnia
|
N/A | |
Completed |
NCT02515006 -
Impact of Homeopathy for Persistent Insomnia in Patients With Cancer
|
N/A | |
Recruiting |
NCT05247697 -
Mirtazapine for Chronic Insomnia in Older Adults
|
Phase 1 | |
Active, not recruiting |
NCT04350866 -
Enhancing Access to Insomnia Care in VA PCMHI Clinics
|
||
Active, not recruiting |
NCT04366284 -
Optimizing the Scalability of Evidence-Based Behavioral Sleep Medicine Practices With a Digital Health Platform
|
N/A | |
Recruiting |
NCT04761796 -
Sleep Time and Insomnia Factors Among Professional Flight Members
|
||
Completed |
NCT02688569 -
Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study
|
N/A | |
Completed |
NCT02236845 -
Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients
|
N/A | |
Completed |
NCT01949389 -
Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders
|
N/A | |
Completed |
NCT00414102 -
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.
|
Phase 4 | |
Completed |
NCT00671294 -
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.
|
Phase 3 | |
Completed |
NCT02392000 -
Mobile Sleep Intervention for OEF, OIF and OND Veterans
|
N/A | |
Recruiting |
NCT04471168 -
Interest of Auriculotherapy in the Management of Chronic Insomnia
|
N/A | |
Completed |
NCT02774642 -
Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)
|
N/A | |
Completed |
NCT02290405 -
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
|
||
Completed |
NCT05618002 -
Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
|
||
Completed |
NCT01995838 -
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
|
Phase 2 | |
Recruiting |
NCT05457790 -
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
|
N/A | |
Completed |
NCT02272712 -
The Effectiveness of Online Treatment for Insomnia in Cancer Survivors
|
N/A | |
Completed |
NCT00915135 -
Efficacy and Safety of Ramelteon on Chronic Insomnia
|
Phase 2 |